The hERG1 Potassium Channel Behaves As Prognostic Factor In Gastric Dysplasia Endoscopic Samples.

Autor: Lastraioli E; Department of Experimental and Clinical Medicine, Section of Internal Medicine, University Of Florence, Florence 50134, Italy., Romoli MR; Department of Experimental and Clinical Medicine, Section of Internal Medicine, University Of Florence, Florence 50134, Italy., Iorio J; Department of Experimental and Clinical Medicine, Section of Internal Medicine, University Of Florence, Florence 50134, Italy., Lottini T; Department of Experimental and Clinical Medicine, Section of Internal Medicine, University Of Florence, Florence 50134, Italy., Chiudinelli M; Pathology Division, Esine Hospital, ASST della Valcamonica, Esine, BS 25040, Italy., Bencivenga M; Surgery Division, University of Verona, Verona 37134, Italy., Vindigni C; Pathology Division, Azienda Ospedaliero-Universitaria Senese, Siena 53100, Italy., Tomezzoli A; Pathology Division, Borgo Trento Hospital, Verona 37134, Italy., De Manzoni G; Surgery Division, University of Verona, Verona 37134, Italy., Compagnoni B; Surgery Division, Esine Hospital, ASST della Valcamonica, Esine, BS 25040, Italy., Manzi I; Gastroenterology and Endoscopy Unit, Morgagni-Pierantoni Hospital, Forlì 47121, Italy., Messerini L; Department of Experimental and Clinical Medicine, Section of Internal Medicine, University Of Florence, Florence 50134, Italy., Saragoni L; Pathology Division, Morgagni-Pierantoni Hospital, Forlì 47121, Italy., Arcangeli A; Department of Experimental and Clinical Medicine, Section of Internal Medicine, University Of Florence, Florence 50134, Italy.
Jazyk: angličtina
Zdroj: OncoTargets and therapy [Onco Targets Ther] 2019 Nov 07; Vol. 12, pp. 9377-9384. Date of Electronic Publication: 2019 Nov 07 (Print Publication: 2019).
DOI: 10.2147/OTT.S226257
Abstrakt: Purpose: Gastric cancer (GC) is still a relevant health issue worldwide. The identification of prognostic factors for progression of gastric dysplasia (GD), the main pre-cancerous lesion of the intestinal-type GC, is hence mandatory.
Patients and Methods: A cohort of 83 GD endoscopic samples belonging to Italian subjects was collected. hERG1 expression was evaluated by immunohistochemistry and scored 0-3, depending on the percentage of stained cells. Expression data were analysed in conjunction with clinico-pathological and survival data.
Results: hERG1 turned out to be expressed in 67.47% (56 out of 83) of the GD samples. hERG1 expression was higher in high-grade GD compared to low-grade GD (29 out of 39, 74.36% vs 27 out of 44, 61.36%), although the statistical significance was not reached (P=0.246). No association emerged between hERG1 expression and clinical features of the patients (age, gender, localization, H. pylori infection, gastritis and intestinal metaplasia). In a subset of cases for which sequential samples of gastric lesions (from GD to Early Gastric Cancer and Advanced Gastric Cancer) were available, hERG1 expression was maintained in all the steps of gastric carcinogenesis from GD onwards. A general trend to increased expression in advanced lesions was observed. hERG1 score had a statistically significant impact on both Progression-Free Survival (P=0.018) and Overall Survival (P=0.031). In particular, patients displaying a high hERG1 score have a shorter survival.
Conclusion: hERG1 is aberrantly expressed in human GD samples and has an impact on both PFS and OS, hence representing a novel prognostic marker for progression of GD towards GC of the intestinal histotype. Once properly validated, hERG1 detection could be included in the clinical practice, during endoscopic surveillance protocols, for the management of GD at higher risk of progression, as already proposed for Barrett's oesophagus.
Competing Interests: The author reports no conflicts of interest in this work.
(© 2019 Lastraioli et al.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje